Biotech is making great strides in oncology.
“I think we are within striking distance of curing some cancers or actually improving survival rates to 90% or above,” AstraZeneca plc (NYSE: AZN) CEO Pascal Soriot told CNBC of the field.
Progress is partly owed to diagnostics. Tech advancements have enabled physicians to catch cancer at earlier stages, and the diagnostic speed continues to improve.
“We are now close enough to be able to diagnose cancer very early on, and the earlier you diagnose cancer, the better chance you have to cure the patient,” Soriot said.
Treatments are improving, too. In the last few months, the field has celebrated positive trial results for AstraZeneca’s Lynparza and Imfinzi, Myovant Sciences Ltd (NYSE: MYOV)’s Relugolix, Diffusion Pharmaceuticals Inc (NASDAQ: DFFN)’s Trans Sodium Crocetinate, Seattle Genetics, Inc. (NASDAQ: SGEN)’s tucatinib and Mirati Therapeutics Inc (NASDAQ: MRTX)’s MRTX849.
Patients are also being offered more and diverse therapeutic techniques. AstraZeneca is investing in many of them, including in antibody conjugates and cell therapy. But the company is staying out of one of the trendier fields: gene therapy.
“Not because we don’t believe in it, not because it has no place,” Soriot said. “It certainly has a great place, but we can’t be everywhere.”
If a treatment has potential, somebody is on it. Nascent cancer companies file for IPOs almost weekly to expand a dense field already held by Bristol-Myers Squibb Co (NYSE: BMY), Celgene Corporation (NASDAQ: CELG), Merck & Co. Inc. (NYSE: MRK), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) and dozens and dozens more.
10 Biopharmaceutical Companies Trying To Cure Cancer
Biotech Stock On The Radar: Alkermes At A Crossroads
See more from Benzinga
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.